The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
Open accessAbstract
Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI‐3, which began on August 1, 2016, is a 5‐year renewal of the current ADNI‐2 study. Methods: ADNI‐3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI‐3 will aim to inform AD treatment trials and facilitate development of AD disease‐modifying treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“Beginning with AD candidate genes nominated by large genome-wide association studies [74], sequencing studies (e.”
BackgroundSelf-citationStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Alsop, D. C., Detre, J. A., Golay, X., Günther, M., Hendrikse, J., Hernandez‐Garcia, L., Lu, H., MacIntosh, B. J., Parkes, L. M., Smits, M., et al. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25197 · Cited by 2,206
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 2×
“Despite some early hopes, brain Ab burden, measured with amyloid PET or in CSF, does not correlate well with disease severity and has not yet been proven an effective surrogate outcome [42,43].”
BackgroundSelf-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
The Alzheimer's Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525
Self-citationPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Self-citationIncidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationThe Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“Second, it will investigate other signals such as change in CSF biomarkers, and functional imaging techniques ([(18)F]-fluorodeoxyglucose-PET (FDG-PET), arterial spin labeling (ASL) perfusion MRI, and task-free functional MRI (TF-fMRI) that may detect treatment effects in phase 2 trials [54]).”
BackgroundSelf-citationAl-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760
Self-citationA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
Self-citationYushkevich, P. A., Pluta, J. B., Wang, H., Xie, L., Ding, S.-L., Gertje, E. C., Mancuso, L., Kliot, D., Das, S. R., & Wolk, D. A. (2015) · Human Brain Mapping · doi:10.1002/hbm.22627 · Cited by 599
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Weiner, M. W., Aisen, P. S., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Shaw, L., Saykin, A. J., Morris, J. C., Cairns, N., Beckett, L. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.007 · Cited by 599
Self-citationEffects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Self-citationTau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 1×
“Recently, [(18)F]-T807 (also known as AV-1451) and other tau PET ligands have been developed to detect tau in humans [52], raising the possibility that tau PET could ultimately be used as a surrogate marker for AD clinical trials.”
BackgroundThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.172 · Cited by 476
Self-citationLandau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M., Mathis, C. A., Jagust, W. J., & Mintun, M. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109009 · Cited by 462
Self-citationBittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
Self-citationMeta-analysis of amyloid-cognition relations in cognitively normal older adults
Hedden, T., Oh, H., Younger, A. P., & Patel, T. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828ab35d · Cited by 319
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans
Saykin, A. J., Shen, L., Yao, X., Kim, S., Nho, K., Risacher, S. L., Ramanan, V. K., Foroud, T. M., Faber, K. M., Sarwar, N., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.009 · Cited by 306
Self-citationSuspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., Jagust, W., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 306
Self-citationQualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., Soares, H., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 298
Self-citationAmyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., Pontecorvo, M., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 294
Self-citationAndrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Self-citationCerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Self-citationA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Donohue, M. C., Green, R. C., Harvey, D., Jack, C. R., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.04.005 · Cited by 239
Self-citationfor the AIBL Research Group, Maruff, P., Lim, Y. Y., Darby, D., Ellis, K. A., Pietrzak, R. H., Snyder, P. J., Bush, A. I., Szoeke, C., Schembri, A., et al. (2013) · BMC Psychology · doi:10.1186/2050-7283-1-30 · Cited by 239
Alterations in metabolic pathways and networks in Alzheimer’s disease
Kaddurah-Daouk, R., Zhu, H., Sharma, S., Bogdanov, M., Rozen, S. G., Matson, W., Oki, N. O., Motsinger-Reif, A. A., Churchill, E., Lei, Z., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.18 · Cited by 205
Self-citationAmariglio, R. E., Donohue, M. C., Marshall, G. A., Rentz, D. M., Salmon, D. P., Ferris, S. H., Karantzoulis, S., Aisen, P. S., & Sperling, R. A. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3375 · Cited by 198
Self-citationEstimating long‐term multivariate progression from short‐term data
Donohue, M. C., Jacqmin‐Gadda, H., Le Goff, M., Thomas, R. G., Raman, R., Gamst, A. C., Beckett, L. A., Jack, C. R., Weiner, M. W., Dartigues, J., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.003 · Cited by 197
Self-citationJahanshad, N., Rajagopalan, P., Hua, X., Hibar, D. P., Nir, T. M., Toga, A. W., Jack, C. R., Saykin, A. J., Green, R. C., Weiner, M. W., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216206110 · Cited by 177
Self-citationGenetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers
Initiative, F. T. A. D. N., Shen, L., Thompson, P. M., Potkin, S. G., Bertram, L., Farrer, L. A., Foroud, T. M., Green, R. C., Hu, X., Huentelman, M. J., et al. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9262-z · Cited by 174
Self-citationReport of the task force on designing clinical trials in early (predementia) AD
Aisen, P. S., Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., Feldman, H. H., Petersen, R. C., Siemers, E., Doody, R. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318207b1b9 · Cited by 172
Self-citationde Florès, R., Joie, R. L., Landeau, B., Perrotin, A., Mézenge, F., Sayette, V. D. L., Eustache, F., Desgranges, B., & Chételat, G. (2014) · Human Brain Mapping · doi:10.1002/hbm.22640 · Cited by 166
The Multilingual Naming Test in Alzheimer's Disease: Clues to the Origin of Naming Impairments
Ivanova, I., Salmon, D. P., & Gollan, T. H. (2013) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617712001282 · Cited by 163
Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy
Ossenkoppele, R., Schonhaut, D. R., Baker, S. L., O’Neil, J. P., Janabi, M., Ghosh, P. M., Santos‐Santos, M., Miller, Z., Bettcher, B. M., Gorno‐Tempini, M. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24321 · Cited by 159
Self-citationLeinenbach, A., Pannee, J., Dülffer, T., Huber, A., Bittner, T., Andreasson, U., Gobom, J., Zetterberg, H., Kobold, U., Portelius, E., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.220392 · Cited by 159
Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 159
Self-citationVellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Self-citationRamanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
Self-citationKorecka, M., Waligórska, T., Figurski, M., Toledo, J. B., Arnold, S. E., Grossman, M., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132489 · Cited by 123
Self-citationBramblett, G. T., Trojanowski, J. Q., & Lee, V. M. (1992) · PubMed · Cited by 115
Self-citationPluta, J., Yushkevich, P., Das, S., & Wolk, D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111931 · Cited by 107
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 104
Self-citationCognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia
Liu‐Seifert, H., Siemers, E., Sundell, K. L., Price, K., Han, B., Selzler, K. J., Aisen, P. S. S., Cummings, J. L., Raskin, J., & Mohs, R. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140792 · Cited by 94
Self-citationWeiner, M. W., Veitch, D. P., Hayes, J., Neylan, T. C., Grafman, J. H., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.005 · Cited by 89
Self-citationIntraindividual cognitive decline using a brief computerized cognitive screening test
Darby, D., Pietrzak, R. H., Fredrickson, J., Woodward, M., Moore, L., Fredrickson, A., Sach, J., & Maruff, P. T. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.009 · Cited by 86
Age and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials
Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3758 · Cited by 85
Self-citationPrevention trials in Alzheimer's disease: An EU-US task force report
Vellas, B. J., Aisen, P. S. S., Sampaio, C., Carrillo, M. C., Scheltens, P., Scherrer, B., Frisoni, G. B., Weiner, M. W., Schneider, L. S. S., Gauthier, S. G., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.014 · Cited by 85
Self-citationMoving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease
Aisen, P. S. S., Vellas, B. J., & Hampel, H. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3842-c1 · Cited by 81
Self-citationEffect of study partner on the conduct of Alzheimer disease clinical trials
Grill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., & Karlawish, J. H. (2012) · Neurology · doi:10.1212/wnl.0b013e31827debfe · Cited by 72
Self-citationSano, M., Raman, R., Emond, J. A., Thomas, R. G., Petersen, R. C., Schneider, L. S., & Aisen, P. S. S. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181f883b7 · Cited by 61
Self-citationMotsinger‐Reif, A. A., Zhu, H., Kling, M. A., Matson, W. R., Sharma, S., Fiehn, O., Reif, D. M., Appleby, D. H., Doraiswamy, P. M., Trojanowski, J. Q., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-28 · Cited by 54
Self-citationRound robin test on quantification of amyloid‐β 1–42 in cerebrospinal fluid by mass spectrometry
Pannee, J., Gobom, J., Shaw, L. M. J., Korecka, M., Chambers, E. E., Lame, M. E., Jenkins, R. G., Mylott, W. R., Jr., Carrillo, M. C., Zegers, I., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1890 · Cited by 53
Self-citationBuilding a roadmap for developing combination therapies for Alzheimer’s disease
Perry, D. P., Sperling, R. A., Katz, R. G., Berry, D. A., Dilts, D. M., Hanna, D. L., Salloway, S., Trojanowski, J. Q., Bountra, C., Krams, M., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.996551 · Cited by 53
Self-citationGerstenecker, A. T., Eakin, A., Triebel, K. L., Martin, R. C., Swenson-Dravis, D. M., Petersen, R. C., & Marson, D. C. (2015) · Psychological Assessment · doi:10.1037/pas0000159 · Cited by 51
Self-citationVellas, B. J., Hampel, H. J., Bugat, M.-È. R., Grundman, M., Andrieu, S., Abushakra, S. R., Bateman, R. J., Berman, R., Black, R. S., Carrillo, M. C., et al. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0044-x · Cited by 45
Self-citationGene-based GWAS and biological pathway analysis of the resilience of executive functioning
Initiative, A. D. N., Mukherjee, S., Kim, S., Ramanan, V. K., Gibbons, L. E., Nho, K. T., Glymour, M. M., Ertekin‐Taner, N., Montine, T. J., Saykin, A. J., et al. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9259-7 · Cited by 42
Self-citationAlzheimer’s disease progression by geographical region in a clinical trial setting
Henley, D. B., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Grill, J. D., Doody, R. S., Aisen, P. S. S., Raman, R., Miller, D. S., Hake, A. M., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0127-0 · Cited by 35
Self-citationSaumier, D., Aisen, P. S. S., Gauthier, S. G., Vellas, B. J., Ferris, S. H., Duong, A., Suhy, J., Oh, J., Lau, W. C., Garceau, D., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0047-4 · Cited by 34
Self-citationMontine, T. J., & Montine, K. S. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150656 · Cited by 34
Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.
Salmon, D. P., Ferris, S. H., Thomas, R. G., Sano, M., Cummings, J. L., Sperling, R. A., Petersen, R. C., & Aisen, P. S. (2013) · Neuropsychology · doi:10.1037/a0032707 · Cited by 32
Self-citationGrill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Hake, A. M., Miller, D. S., Doody, R. S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0122-5 · Cited by 32
Self-citationAlzheimer's Disease Neuroimaging Initiative special issue
Frisoni, G. B., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.006 · Cited by 29
Self-citationMixed model of repeated measures versus slope models in Alzheimer's disease clinical trials
Donohue, M., & Aisen, P. S. S. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0047-7 · Cited by 27
Self-citationThe relative efficiency of time-to-threshold and rate of change in longitudinal data
Donohue, M., Gamst, A. C., Thomas, R. G., Xu, R., Beckett, L. A., Petersen, R. C., Weiner, M. W., & Aisen, P. S. S. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.007 · Cited by 27
Self-citationAlzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease
Thies, W. H. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1883 · Cited by 13
Salloway, S., Sperling, R. A., Gregg, K. M., Yu, P., Joshi, A. D., Lu, M., Mintun, M. A., Pontecorvo, M. J., Booth, K., Wyman, B. T., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.08.250 · Cited by 12
Mueller, S. G., Yushkevich, P. A., Wang, L., Leemput, K. V., Mezher, A. F., Iglesias, J. E., Das, S. R., & Weiner, M. W. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.085 · Cited by 9
Self-citationDonohue, M., Gamst, A. C., & Aisen, P. S. S. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.013 · Cited by 5
Self-citationMueller, S. G., Soher, B., Matson, G. B., Walter, R., Yohannes, S., & Weiner, M. W. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.084 · Cited by 5
Self-citation
Cited by
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
“The utilization of neuroimaging biomarkers in ADRD has become increasingly important as structural, functional and molecular imaging have led to earlier diagnosis [51–53]; disease staging, including prodromal and preclinical stages [54, 55]; and identification of individuals for clinical trial participation [56].”
BackgroundVeitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.005 · Cited by 454
Self-citationThe Lifespan Human Connectome Project in Aging: An overview
Bookheimer, S. Y., Salat, D. H., Terpstra, M., Ances, B. M., Barch, D. M., Buckner, R. L., Burgess, G. C., Curtiss, S. W., Diaz-Santos, M., Elam, J. S., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2018.10.009 · Cited by 431
Olfactory and other sensory impairments in Alzheimer disease
Murphy, C. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0097-5 · Cited by 425
Metadata
- Authors
- Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Salazar, J., Saykin, A. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-12-05
- Volume
- 13
- Issue
- 5
- Pages
- 561-571
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2560584411
- Cited by
- 479
- References
- 85
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.